LifeMD Inc insiders have been active in the stock market, sending signals that investors are closely watching. On November 24, 2025, FRIEDEMAN JESSICA purchased 20,000 shares of LifeMD Inc, spending a total of $80,800 at $4.04 per share.
Meanwhile, ALVAREZ NICHOLAS P has been both buying and selling significant amounts of stock. Recently, he sold 75,000 shares at $5.92 each, netting over $443,760, leaving him with 605,000 shares. Prior to this sale, Alvarez had acquired 75,000 shares at $6.12 per share for a total of $459,000.
Analyst Ratings
LifeMD Inc has received positive attention from analysts. On June 18, 2025, BTIG Research retained LifeMD with a “Buy” rating and increased the price target to $18. Lake Street also initiated coverage with a “Buy” rating in early December. On the other hand, Mizuho began coverage on December 4, 2024, with a “Neutral” rating.
Stock Performance
LifeMD Inc [NASDAQ: LFMD] saw a decline in its last trading session, dropping 2.29% to $3.84. The stock traded as low as $3.78 and as high as $3.945 during the session. Over the past five days, the stock has fallen approximately 3.76%, and over the past year, shares have dropped around 33.79%. The 52-week high was $15.84 on June 23, 2025, and the 52-week low was $3.43 on November 18, 2025.
Support And Resistance
Current technical levels show support at $3.76, with a potential drop to $3.67 if broken. Resistance is seen at $3.95, with the next level at $4.05. The 14-day RSI sits at 24.16, indicating that the stock is in oversold territory.
Short Interest
Short interest in LifeMD Inc has risen recently. On November 14, 2025, short interest increased by 0.22 million shares to 4.39 million. This represents a 4.91% jump from the previous figure of 4.17 million on October 15, 2025. Although short shares make up only 4.88% of the float, the days-to-cover ratio has climbed to 4.88.
Institutional Holdings
Analyst price targets for LifeMD Inc suggest optimism. FactSet reports an average target of $8 over the next 12 months, a potential rise of over 100% from the current price of $3.93. Analysts expect the stock to reach $18, with the lowest target at $6. Four analysts have given the stock a “Buy” rating as of the end of 2025. KeyBanc Capital Markets assigned an “Overweight” rating and a $12 price target on June 5, 2024.
